3 assets in Lung Carcinoma In Situ

Therapeutic assets addressing Lung Carcinoma In Situ, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Infliximab Lung Carcinoma In Situ	M.D. Anderson Cancer Center	P1	CC (43)
Prednisone Lung Carcinoma In Situ	M.D. Anderson Cancer Center	P1	CC (43)
Vedolizumab Lung Carcinoma In Situ	M.D. Anderson Cancer Center	P1	CC (43)